Overcoming the challenges of noninvasive protein and peptide delivery

American Pharmaceutical Review

Volumn 6, Issue 4, 2003, Pages 21-30

  DeFelippis, Michael R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CITRIC ACID; CYCLODEXTRIN; DEOXYCHOLATE SODIUM; DEOXYRIBONUCLEASE; DESMOPRESSIN; DODECYL SULFATE SODIUM; DRUG ADDITIVE; EDETIC ACID; GLUCAGON LIKE PEPTIDE; GLYCEROL OLEATE; GLYCOCHOLATE SODIUM; INSULIN; MICROSPHERE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTANOIC ACID; OLEIC ACID; OXYTOCIN; PEPTIDE; POLIDOCANOL; PROTEIN; SALICYLIC ACID DERIVATIVE; TAUROCHOLIC ACID; TAURODIHYDROFUSIDATE;

BIOTECHNOLOGY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG PENETRATION; DRUG RESEARCH; DRY POWDER; ELECTROSPRAY; ENCAPSULATION; FREEZE DRYING; GENOMICS; HUMAN; INFUSION PUMP; NEBULIZER; NEEDLE; PHYSICAL CHEMISTRY; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SITE DIRECTED MUTAGENESIS; SYRINGE; UNITED STATES;

EID: 0347600479     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. PhRMA Survey. "371 Biotechnology medicines in testing promise to bolster the arsenal against disease". New Medicines in Development Biotechnology 1-47 (2002).
2. Edwards, A.M., Arrowsmith, C.H., des Pallieres, B. Proteomics: new tools for a new era. Mod. Drug Discov. 3, 35-44 (2000).
3. Akers, M.J., DeFelippis, M.R. Peptides and proteins as parenteral solutions. In Pharmaceutical Formulation Development of Peptides and Proteins. Eds. Frokjaer, S., Hovgaard, L., Taylor & Francis, London, 145-177 (2000).
4. Breimer, D.D. Future challenges for drug delivery. J. Control. Rel. 62, 3-6 (1999).
5. Brange, J., Owens, D.R., Kang, S., Vølund, A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13, 923-954 (1990).
6. DeFelippis, M.R., Chance, R.E., Frank, B.H. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit. Rev. Ther. Drug Carrier Syst. 18, 201-264 (2001).
7. Cleland, J.L., Powell, M.F., Shire, S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307-377 (1993).
8. Robertson, K.E., Glazer, N.B., Campbell, R.K. The latest developments in insulin injection devices. Diabetes Educr. 26, 135-152 (2000).
9. Burkoth, T.L., Bellhouse, B.J., Hewson, G. Transdermal and transmucosal powdered drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 16, 331-384 (1999).
10. Yang, M.X., Shenoy, B., Disttler, M, Patel, R., McGrath, M., Pechenov, S., Margolin, A.L. Crystalline monoclonal antibodies for subcutaneous delivery. Proc. Natl. Acad. Sci. 100, 6934-6939 (2003).
11. Langer, R. Controlled release of a therapeutic protein. Nature Med. 2, 742-743 (1996).
12. Ibbotson, T., Goa, K.L. Darbepoetin Alfa. Drugs 2001 61, 2097-2104 (2001).
13. Elliott S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck L., Busse, L., Chang, D., Fuller, J., Grant, J., Hernday, N., Hokum, M., Hu, S., Knudten, A., Levin, N., Komorowski, R., Martin, F., Navarro, R., Osslund, T., Rogers, G., Rogers, N., Trail, G., Egrie, J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nature Biotech. 21, 414-421 (2003).
14. Harris, J.M., Chess, R.B. Effect of pegylation on pharmaceuticals. Nature Rev. 2, 214-221 (2003).
15. Zhou, X.H. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Rel. 29, 239-252 (1994).
16. Lee, V.H.L., Yamamoto, A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Del. Rev. 4, 171-207 (1990).
17. Sayani, A.P., Chien, Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13, 85-184 (1996).
18. Johansson, F., Hjertberg, E., Eirefelt, S., Tronde, A., Bengtsson, U.H. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17, 63-71 (2002).
19. Hinchcliffe, M., Illum, L. Intranasal insulin delivery and therapy. Adv. Drug Del. Rev. 35 199-234 (1999).
20. Gizurarson, S., Bechgaard, E. Study of nasal enzyme activity towards insulin. in vitro. Chem. Pharm. Bull. 39, 2155-2157 (1991).
21. Chien Y.W., Chang, S.-F. Intranasal drug delivery for systemic medications. Crit. Rev. Ther. Drug Carrier Syst. 4, 67-180 (1987).
22. Chetty, D.J., Chien, Y.W. Novel methods of insulin delivery: an update. Crit. Rev. Ther. Drug Carrier Syst. 15, 629-670 (1998).
23. Heinemann, L., Pfützner, A., Heise, T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal, and pulmonary insulin delivery. Curr. Pharm. Design 7, 1327-1351 (2001).
24. Owens, D.R. New horizons - alternative routes for insulin therapy. Nature Rev. 1, 529-540 (2002).
25. de Vries, M.E., Boddé, H.E., Verhoef, J.C., Junginger, H.E. Developments in buccal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 8, 217-303 (1991).
26. Veuillez, F., Kalia, Y.N., Jacques, Y., Deshusses, J., Buri, P. Factors and strategies for improving buccal absorption of peptides. Eur. J. Pharmaceut. Biopharm. 51, 93-109 (2001).
27. Senel, S., Kremer, M., Nagy, K., Squier, C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotech. 2, 175-186 (2001).
28. Walker, G.F, Langoth, N., Bernkop-Schnürch, A. Peptidase activity on the surface of porcine buccal mucosa. Int. J. Pharmceut. 233, 141-147 (2002).
29. Harris, D., Robinson, J.R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 81, 1-10 (1992).
30. Gutniak, M.K., Larsson, H., Sanders, S.W., Juneskans, O., Holst, J.J., Ahrén, B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20, 1874-1879 (1997).
31. Modi, P., Mihic, M., Lewin, A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab. Res. Rev. 18, S38-S42 (2002).
32. Naik, A., Kalia, Y.N., Guy, R.H. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today. 3, 318-326 (2000).
33. Merino, V., Kalia, Y.N., Guy, R.H. Transdermal therapy and diagnosis by iontophoresis. TIBTECH 15, 288-290 (1997).
34. Santi, P., Colombo, P., Bettini, R., Catellani, P.L., Minutello, A., Volpato, N.M., Drug Reservoir Composition and Transport of Salmon Calcitonin in Transdermal Iontophoresis. Pharm. Res. 14, 63-66 (1997).
35. Langkjœr, L., Brange, J., Grodsky, G.M., Guy, R.H. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J. Control. Rel. 51, 47-56 (1998).
36. Mitragotri, S., Blankschtein, D., Langer R. Ultrasound-mediated transdermal protein delivery. Science 269, 850-853 (1995).
37. Cevc, G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 13, 257-388 (1996).
38. Smith, A.M., Eppstein, J.A., Delcher, H.K., McRae, M.S., Woods, T.J., Williams, D.J., Hatch, M.R. Transdermal insulin infusion through thermally created micropores in humans. Diabetes 50, A132 (2001).
39. McAllister, D.V., Allen, M.G., Prausnitz, M.R. Microfabricated microneedles for gene and drug delivery. Annu. Rev. Biomed. Eng. 2, 289-313 (2000).
40. Pettit, D.K., Gombotz, W.R. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. TIBTECH 16, 343-349 (1998).
41. Christopher, F., Chase, D., Stein, K., Milne, R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J. Clin. Pharmacy Therapeut. 24, 415-426 (1999).
42. Patton, J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Del. Rev. 19, 3-36 (1996).
43. Byron, P.R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 75, 433-438 (1986).
44. Crowder, T.M., Louey, M.D., Sethuraman, V.V., Smyth, H.D.C., Hickey, A.J. 2001: an odyssey in inhaler formulation and design. Pharm. Tech. 25, 99-113 (2001).
45. Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Deaver, D., Lotan, X., Langer, R. Large porous particles for pulmonary drug delivery. Science 276, 1868-1871 (1997).
46. Edwards, D.A., Ben-Jebria, A., Langer, R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 84, 379-385 (1998).
47. Vanbever, R., Mintzes, J.D., Wang, J., Nice J,. Chen, D., Batycky, R., Langer, R., Edwards, D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 16, 1735-1742 (1999).
48. Adjei, A.L., Carrigan, P.J. Pulmonary bioavailability of LH-RH analogs: some biopharmaceutical guidelines. J. Biopharm. Sci. 3, 247-254 (1992).
49. Byron, P.R., Patton, J.S. Drug delivery via the respiratory tract. J. Aerosol Med. 7, 49-75 (1994).
50. Patton, J.S., Bukar, J., Nagarajan, S. Inhaled insulin. Adv. Drug Del. Rev. 35, 235-247 (1999).
51. Heinemann, L., Traut, T., Heise, T. Time-action profile of inhaled insulin. Diabetic Med. 14, 63-72 (1997).
52. Skyler J.S., Cefalu, W.T., Kourides, I.A., Landschulz, W.H., Balagtas, C.C., Cheng, S.-L., Gelfand, R.A. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 357, 331-335 (2001).
53. Wilson, B.R., Grant, M.L., Steiner, S.S., Pohl, R. TECHNOS-PHERES™ for pulmonary and nasal applications. Respiratory. Drug Del. VIII May 12-16 (2002).
54. Vanbever, R., Ben-Jebria, A., Mintzes, J.D., Langer, R., Edwards, D.A. Sustained release of insulin from insoluble inhaled particles. Drug Dev. Res. 48, 178-185 (1999).
55. Hardy, J.G., Chadwick, T.S. Sustained release drug delivery to the lungs. Clin. Pharmacokinet. 39, 1-4 (2000).
56. Woodley, J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11, 61-95 (1994).
57. Fasano, A. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci. 87, 1351-1356 (1998).
58. Sood, A., Panchagnula, R. Peroral route: an opportunity for protein and peptide drug delivery. Chem. Rev. 101, 3275-3303 (2001).
59. Lee, H.J. Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 25, 572-584 (2002).
60. Shah, R.B., Ahsan, F., Khan, M.A. Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19, 135-169 (2002).
61. Goldberg, M., Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nature Rev. 2, 289-295 (2003).
62. Bernkop-Schnürch, A., Walker, G. Multifunctional matrices for oral peptide delivery. Crit. Rev. Ther. Drug Carrier Syst. 18, 459-501 (2001).
63. Carino, G.P., Jacob, J.S., Mathiowitz, E. Nanosphere based oral insulin delivery. J. Control. Rel. 65, 261-269 (2000).
64. Carino, G.P., Mathiowitz, E. Oral insulin delivery. Adv. Drug Del. Rev. 35, 249-257 (1999).
65. Allémann, E., Leroux, J.-C., Gurney, R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Del. Rev. 34, 171-189 (1998).
66. Yang, C.Y., Dantzig, A.H., Pidgeon, C. Intestinal peptide transport systems and oral drug availability. Pharm. Res. 16, 1331-1343 (1999).
67. Leone-Bay, A., Paton, D.R., Weidner, J.J. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med. Res. Rev. 20, 169-186 (2000).
68. Leone-Bay, A., Leipold, H., Paton, D.R., Milstein, S.J., Baughman, R.A. Oral delivery of rhGH: preliminary mechanistic considerations. DN&P 9, 586-591 (1996).
69. Milstein, S.J., Leipold, H., Sarubbi, D., Leone-Bay, A., Mlynek, G.M., Robinson, J.R., Kasimova, M., Freire, E. Partially unfolded proteins efficiently penetrate cell membranes - implications for oral drug delivery. J. Control. Rel. 53, 259-267 (1998).
70. Buclin, T., Rochat, M.C., Burckhardt, P., Azria, M., Attinger, M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J. Bone Mineral Res. 17, 1478-1485 (2002).
71. Leone-Bay, A., Sato, M., Paton, D., Hunt, A.H., Sarubbi, D., Carozza, M., Chou, J., McDonough, J., Baughman, R.A. Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18, 964-970 (2001).
72. Still, J.G. Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18, S29-S37 (2002).
73. Clement, S., Still, J.G., Kosutic, G., McAllister R.G. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Tech. Therapeut. 4, 459-466 (2002).
74. Kipnes, M., Dandona, P., Tripathy, D., Still, J.G., Kosutic, G. Control of postprandial plasma glucose by an oral insulin product (HIM2) inpatients with type 2 diabetes. Diabetes Care 26, 421-426 (2003).
75. Rios, M. Emerging research opportunities in oral inhalation technology. Pharm. Tech. 27, 42-49 (2003).